Parabilis Medicines vs Doximity

Side-by-side comparison of AI visibility scores, market position, and capabilities

Doximity leads in AI visibility (86 vs 52)
Parabilis Medicines logo

Parabilis Medicines

ChallengerHealthcare & Life Sciences

AI Peptide Therapeutics

Clinical-stage biotech; raised $305M Series F (Jan 2026) for AI-optimized peptides targeting intracellular cancer proteins previously considered undruggable; oncology-first pipeline

AI VisibilityBeta
Overall Score
C52
Category Rank
#302 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
54
Gemini
58

About

Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.

Full profile
Doximity logo

Doximity

GrowthHealthTech

Physician Professional Network

Doximity (NYSE: DOCS), professional network for US physicians with 2M+ verified clinicians; telehealth, medical news, and career tools monetized via pharmaceutical digital marketing.

AI VisibilityBeta
Overall Score
A86
Category Rank
#6 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
85
Perplexity
84
Gemini
88

About

Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinicians on the platform — representing the majority of practicing US physicians — Doximity has established itself as the dominant professional network for doctors, providing identity-verified peer connections, specialty-specific news feeds, medical journal access, and career management tools including a physician job board and CV builder. The verification layer distinguishes Doximity from general professional networks and makes it the standard reference for confirming physician credentials and contact information across the healthcare industry.

Full profile

AI Visibility Head-to-Head

52
Overall Score
86
#302
Category Rank
#6
79
AI Consensus
85
stable
Trend
stable
49
ChatGPT
85
54
Perplexity
84
58
Gemini
88
51
Claude
81
52
Grok
85

Key Details

Category
AI Peptide Therapeutics
Physician Professional Network
Tier
Challenger
Growth
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Parabilis Medicines
AI Peptide Therapeutics
Only Doximity
Physician Professional Network

Integrations

Only Parabilis Medicines

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.